Provided by Tiger Trade Technology Pte. Ltd.

Incyte

121.35
-1.8500-1.50%
Post-market: 121.350.00000.00%19:30 EDT
Volume:1.62M
Turnover:197.60M
Market Cap:24.60B
PE:15.46
High:124.23
Open:123.00
Low:121.03
Close:123.20
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.11
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.88
PE(LYR):18.93

Loading ...

Incyte Posts 24-Week TRuE-AD4 Data on Long-Term Safety of Ruxolitinib Cream in Moderate Atopic Dermatitis at EADV 2026

Reuters
·
Sep 22

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

Incyte Expands Skin Diseases Treatment Partnership in Australia

MT Newswires Live
·
Sep 21

Specialised Therapeutics expands partnership with Incyte to include Opzelura

TIPRANKS
·
Sep 21

AFLAC, CME, Incyte, Box, Five Below Insider Shake-Up

TIPRANKS
·
Sep 19

Incyte Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 18

Incyte R&D President Pablo J. Cagnoni Disposes of 23,218 Common Shares Worth $2.8 Million

Reuters
·
Sep 18

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 17

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 16

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 11

Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program

MT Newswires Live
·
Sep 10

Incyte Announces Funding of Minjuvi® (Tafasitamab) for Patients with Relapsed or Refractory Follicular Lymphoma Through Ontario's Fast Program

THOMSON REUTERS
·
Sep 10

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 09

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 02

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 01

Incyte Reaches CMS Pact on Jakafi Medicaid Pricing

TIPRANKS
·
Sep 01

Incyte - Expects Exemption from Future CMS Pricing Mandates Including Guard and Globe - SEC Filing

THOMSON REUTERS
·
Sep 01

Incyte - Announces Agreement with CMS to Improve Medicine Access - SEC Filing

THOMSON REUTERS
·
Sep 01

Incyte - State Medicaid to Access Jakafi and Jakafi Xr at Prices Aligned with Advanced Nations - SEC Filing

THOMSON REUTERS
·
Sep 01

Incyte - Does not Expect Agreement to Affect 2026 Financial Guidance or Outlook - SEC Filing

THOMSON REUTERS
·
Sep 01